Autoimmune-Summaries: Daily Autoimmune Updates at a Glance
- decodeMR Team
- Apr 1
- 1 min read
31/03/2026
Galapagos and Gilead entered into a binding agreement to collaborate on advancing a T cell engager program for autoimmune diseases (Ref)
Galapagos and Gilead Sciences entered into a binding collaboration agreement to co-develop gamgertamig (OM336; BCMAxCD3 T cell engager) originally developed by Ouro Medicines targeting deep B-cell depletion for autoimmune diseases
Galapagos agreed to pay 50% of Gilead's $1.675B upfront acquisition cost of Ouro Medicines and committed to fund all gamgertamig development costs through initiation of registrational studies, after which costs were shared 50/50
Galapagos was made eligible for up to $100M in development milestones and was set to receive tiered royalties of 20–23% on net sales upon commercialization; Gilead retains exclusive worldwide commercialization rights excluding Kymed’s territories
The collaboration also includes three additional Ouro preclinical autoimmune programs, with Gilead holding an option to co-develop each at $75M per program for a 50/50 profit share post-clinical proof-of-concept
